Valuation : Repare Therapeutics Inc.

Market Cap 112M 96.45M 90.74M 82.89M 155M 10.58B 155M 1.07B 416M 5.43B 421M 412M 17.49B P/E 2023
-3.28x
P/E 2024 -0.66x
Enterprise Value -38.78M -33.37M -31.39M -28.68M -53.65M -3.66B -53.79M -371M -144M -1.88B -146M -142M -6.05B EV / Sales 2023
1,707,888x
EV / Sales 2024 -1,779,624x
Free-Float
99.77%
Yield 2023 *
-
Yield 2024 -
1 day+0.76%
Current year+1.92%
Current year 2.5
Extreme 2.5
2.65
1 year 1.65
Extreme 1.65
2.66
3 years 0.89
Extreme 0.89
13.85
5 years 0.89
Extreme 0.89
34.21
10 years 0.89
Extreme 0.89
46.44
Manager TitleAgeSince
President - 28/01/2026
Director TitleAgeSince
Director/Board Member - 28/01/2026
Date Insider Type Main position Quantity % Market Cap. Importance
28/1/26 Issuer sale

Chief Executive Officer

1,167,586 2.7085%
28/1/26
BVF Partners LP
TenderCompany 10,166,943 23.5846%
28/1/26 Issuer sale

Chairman

7,500 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%-.--%+56.80%-72.22% 114M
-2.54%-2.84%-1.77%+14.72% 48.93B
-0.40%+1.03%+418.57%+523.39% 45.01B
-1.42%+2.30%+42.67%+21.22% 44.07B
-1.22%-2.31%+4.82%+74.90% 40.73B
+0.53%-1.36%+16.87%+47.12% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+123.04% 16.5B
-1.01%+0.50%+13.91%+31.45% 14.67B
-1.65%-1.03%+75.93%+41.22% 13.77B
Average -0.75%+0.48%+72.14%+89.43% 27.51B
Weighted average by Cap. -1.03%+0.11%+89.41%+127.84%

Financials

2023 2024
Net sales 51.13 44 41.4 37.82 70.74 4.83K 70.94 489.19 189.83 2.48K 192.01 187.82 7.98K 53.48 46.02 43.3 39.55 73.99 5.05K 74.19 511.61 198.53 2.59K 200.81 196.43 8.35K
Net income -93.8M -80.71M -75.94M -69.37M -130M -8.86B -130M -897M -348M -4.54B -352M -345M -14.64B -84.69M -72.87M -68.57M -62.63M -117M -8B -117M -810M -314M -4.1B -318M -311M -13.22B
Net Debt -220M -189M -178M -163M -305M -20.79B -306M -2.11B -818M -10.67B -827M -809M -34.37B -151M -130M -122M -112M -209M -14.24B -209M -1.44B -560M -7.31B -566M -554M -23.54B
Logo Repare Therapeutics Inc.
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Employees
129
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. RPTX Stock